Location [1]
Protein [2]
Ephrin type-A receptor 2
Synonyms [1]

The EPH receptor A2 (EPHA2) gene is a member of the protein-tyrosine kinase subfamily of ephrin receptors and encodes a protein that associates with ephrin-A ligands. Missense mutations, nonsense mutations, silent mutations, and EPHA2 overexpression are observed in cancers such as biliary tract cancers, skin cancer, and stomach cancer.

EPHA2 is altered in 0.46% of all cancers with conventional glioblastoma multiforme, skin squamous cell carcinoma, colorectal adenocarcinoma, head and neck squamous cell carcinoma, and anaplastic oligodendroglioma having the greatest prevalence of alterations [3].

EPHA2 GENIE Cases - Top Diseases

The most common alterations in EPHA2 are EPHA2 Mutation (1.57%), EPHA2 P571L (0.18%), EPHA2 V364I (0.08%), EPHA2 A112T (0.09%), and EPHA2 A216T (0.07%) [3].

EPHA2 GENIE Cases - Top Alterations

Significance of EPHA2 in Diseases

Malignant Solid Tumor +

Urothelial Carcinoma +

Malignant Glioma +

Malignant Hepatobiliary Neoplasm +

Hepatobiliary Neoplasm +

Pancreatic Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Esophageal Carcinoma +

Gastric Carcinoma +

Gastrointestinal Stromal Tumor +

Lip And Oral Cavity Carcinoma +

Lung Adenocarcinoma +

Malignant Laryngeal Neoplasm +

Malignant Salivary Gland Neoplasm +

Nasal Cavity And Paranasal Sinus Carcinoma +

Nasopharyngeal Carcinoma +

Non-Small Cell Lung Carcinoma +

Oropharyngeal Carcinoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.